Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free CAPS Stock Alerts

Capstone Therapeutics (CAPS) Competitors

Capstone Therapeutics logo
$0.23 -0.01 (-5.88%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$0.23 +0.00 (+0.26%)
As of 07/24/2026 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CAPS vs. AKTX, MAAQ, CTXR, LEXX, and PASG

Should you buy Capstone Therapeutics stock or one of its competitors? MarketBeat compares Capstone Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capstone Therapeutics include Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Citius Pharmaceuticals (CTXR), Lexaria Bioscience (LEXX), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

How does Capstone Therapeutics compare to Akari Therapeutics?

Capstone Therapeutics (NASDAQ:CAPS) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Akari Therapeutics has lower revenue, but higher earnings than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.37N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Akari Therapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-41.26% -114.15% -39.74%
Akari Therapeutics N/A -123.29%-63.01%

Capstone Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

In the previous week, Akari Therapeutics had 5 more articles in the media than Capstone Therapeutics. MarketBeat recorded 6 mentions for Akari Therapeutics and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat Akari Therapeutics' score of 0.77 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Capstone Therapeutics Very Positive
Akari Therapeutics Positive

Akari Therapeutics has a consensus price target of $32.33, indicating a potential upside of 271.65%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

2.6% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Akari Therapeutics beats Capstone Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Capstone Therapeutics compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Mana Capital Acquisition has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Mana Capital Acquisition's return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mana Capital AcquisitionN/A N/A N/A
Capstone Therapeutics -41.26%-114.15%-39.74%

In the previous week, Capstone Therapeutics had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for Mana Capital Acquisition. Capstone Therapeutics' average media sentiment score of 1.87 beat Mana Capital Acquisition's score of 0.00 indicating that Capstone Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Mana Capital Acquisition Neutral
Capstone Therapeutics Very Positive

Mana Capital Acquisition has higher earnings, but lower revenue than Capstone Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mana Capital AcquisitionN/AN/AN/AN/AN/A
Capstone Therapeutics$48.11M0.07-$21.23M-$3.37N/A

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mana Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Capstone Therapeutics beats Mana Capital Acquisition on 5 of the 9 factors compared between the two stocks.

How does Capstone Therapeutics compare to Citius Pharmaceuticals?

Capstone Therapeutics (NASDAQ:CAPS) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Capstone Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Citius Pharmaceuticals has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Citius Pharmaceuticals' return on equity of -61.09% beat Capstone Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-41.26% -114.15% -39.74%
Citius Pharmaceuticals N/A -61.09%-35.36%

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Capstone Therapeutics. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat Citius Pharmaceuticals' score of 0.94 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Capstone Therapeutics Very Positive
Citius Pharmaceuticals Positive

Capstone Therapeutics has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.37N/A
Citius Pharmaceuticals$5.61M2.55-$37.43M-$2.13N/A

Citius Pharmaceuticals has a consensus price target of $5.00, indicating a potential upside of 860.98%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Citius Pharmaceuticals beats Capstone Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Capstone Therapeutics compare to Lexaria Bioscience?

Capstone Therapeutics (NASDAQ:CAPS) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 168.34%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lexaria Bioscience
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Lexaria Bioscience has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Lexaria Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Capstone Therapeutics-41.26% -114.15% -39.74%
Lexaria Bioscience N/A -174.93%-143.89%

In the previous week, Lexaria Bioscience had 3 more articles in the media than Capstone Therapeutics. MarketBeat recorded 4 mentions for Lexaria Bioscience and 1 mentions for Capstone Therapeutics. Capstone Therapeutics' average media sentiment score of 1.87 beat Lexaria Bioscience's score of 0.63 indicating that Capstone Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Capstone Therapeutics Very Positive
Lexaria Bioscience Positive

Lexaria Bioscience has lower revenue, but higher earnings than Capstone Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capstone Therapeutics$48.11M0.07-$21.23M-$3.37N/A
Lexaria Bioscience$194K71.42-$11.90M-$0.34N/A

2.6% of Capstone Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 39.3% of Capstone Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capstone Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Summary

Lexaria Bioscience beats Capstone Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Capstone Therapeutics compare to Passage Bio?

Passage Bio (NASDAQ:PASG) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Passage Bio currently has a consensus price target of $13.25, indicating a potential upside of 168.22%. Given Passage Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Passage Bio is more favorable than Capstone Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Passage Bio
1 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.11
Capstone Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

53.5% of Passage Bio shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 4.9% of Passage Bio shares are held by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Passage Bio has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.51, indicating that its stock price is 251% less volatile than the broader market.

Passage Bio has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Capstone Therapeutics' return on equity of -114.15% beat Passage Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Passage BioN/A -150.88% -59.78%
Capstone Therapeutics -41.26%-114.15%-39.74%

In the previous week, Passage Bio and Passage Bio both had 1 articles in the media. Passage Bio's average media sentiment score of 1.89 beat Capstone Therapeutics' score of 1.87 indicating that Passage Bio is being referred to more favorably in the media.

Company Overall Sentiment
Passage Bio Very Positive
Capstone Therapeutics Very Positive

Capstone Therapeutics has higher revenue and earnings than Passage Bio. Passage Bio is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Passage BioN/AN/A-$45.52M-$11.84N/A
Capstone Therapeutics$48.11M0.07-$21.23M-$3.37N/A

Summary

Passage Bio and Capstone Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Capstone Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPS vs. The Competition

Export
MetricCapstone TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.72M$3.67B$6.87B$12.26B
Dividend YieldN/A2.19%2.67%9.79%
P/E Ratio-0.0721.4827.1423.64
Price / Sales0.07170.08517.0889.45
Price / CashN/A157.9050.5459.64
Price / Book0.177.8810.286.07
Net Income-$21.23M$23.86M$3.60B$331.99M
7 Day Performance-10.39%-3.82%-1.27%-0.63%
1 Month Performance-2.00%-2.61%-0.37%-2.00%
1 Year Performance-85.55%32.79%18.30%13.62%

Capstone Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPS
Capstone Therapeutics
0.7342 of 5 stars		$0.23
-5.9%		N/A-85.6%$3.72M$48.11MN/A38
AKTX
Akari Therapeutics
3.305 of 5 stars		$13.24
-4.6%		$89.00
+572.2%		-80.2%$15.09MN/AN/A9
MAAQ
Mana Capital Acquisition
N/A$1.83
-1.1%		N/A-63.0%$14.87MN/AN/A1
CTXR
Citius Pharmaceuticals
2.1148 of 5 stars		$0.54
-7.3%		$5.00
+825.9%		-69.2%$14.82MN/AN/A20
LEXX
Lexaria Bioscience
2.7184 of 5 stars		$0.58
-10.3%		$1.50
+158.6%		-44.7%$14.38M$368KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CAPS) was last updated on 7/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel